Hadasit Bio-Holdings Ltd. (HDST) surged the most in almost three months after a unit got investigational new drug approval from the U.S. Food and Drug Administration for a Phase II clinical trial for blood clotting.

Shares of the developer of diagnostic and treatment products rallied 10 percent to 0.56 shekel, the most since Dec. 1, at 11:04 a.m. in Tel Aviv.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net